15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Tarsus Pharmaceuticals Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $88.00 to $105.00, so the covering firms are broadly aligned. The average target of $96.40 sits 64% above the current $58.95. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.83 next quarter toward $1.66 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Tarsus Pharmaceuticals Inc.
As of Jul, 5 of 5 firms rate TARS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TARS EPS & revenue forecast
EPS · NEXT QUARTER
$-1.83
Range $-1.96 – $-1.71 · 2 analysts · +512% YoY
Next period, 2 analysts expect Tarsus Pharmaceuticals Inc to earn $-1.83 a share (range $-1.96 – $-1.71), versus $-0.30 a year earlier. Full-year consensus is $-2.25, growing to $1.66 the year after.
REVENUE · NEXT QUARTER
$179.7M
Range $179.0M – $180.4M · 2 analysts · +51% YoY
Revenue is expected to reach $179.7M (range $179.0M – $180.4M), +51.4% year-over-year. Full-year consensus is $712.6M, rising to $900.3M next year.
Top analysts covering Tarsus Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TARS.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$88.00+49.3% to target
Overall win rate
56%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #136
Buy
$89.00+51.0% to target
Overall win rate
46%
+ Follow
#3
Oren Livnat
HC Wainwright & Co. · Rank #142
Buy
$73.00+23.8% to target
Overall win rate
54%
+ Follow
#4
Balaji Prasad
Barclays · Rank #147
Buy
$60.00+1.8% to target
Overall win rate
44%
+ Follow
#5
Francois Brisebois
Oppenheimer · Rank #186
Buy
$105.00+78.1% to target
Overall win rate
40%
+ Follow
TARS stock forecast FAQ
What is TARS's average 12-month price target?+
The 5 analysts with a live target average $96.40 for Tarsus Pharmaceuticals Inc over the next 12 months, ranging from a $105.00 high to a $88.00 low.
Is TARS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TARS?+
The Street-high target is $105.00 (Oppenheimer), and the Street-low is $88.00 (HC Wainwright & Co.). The average of all 5 active targets is $96.40.
How many Wall Street analysts cover TARS?+
5 analysts have an active rating on Tarsus Pharmaceuticals Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering TARS?+
Among analysts who currently cover TARS, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $88.00 target.
What is Tarsus Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.83 per share (range $-1.96 – $-1.71) across 2 analysts. Full-year EPS is projected at $-2.25, rising to $1.66 the following year.
How much revenue is Tarsus Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $179.7M (range $179.0M – $180.4M). Full-year revenue is projected at $712.6M, growing to $900.3M next year.
Have analysts been upgrading or downgrading TARS lately?+
As of Jul, 5 of 5 firms rate TARS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TARS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
